Skip to content

A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles

A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06219278
Enrollment
32
Registered
2024-01-23
Start date
2023-10-29
Completion date
2024-07-01
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wrinkle

Brief summary

This is a retrospective chart review of data from the multi-site prospective clinical trial, Functional Usability and Feasibility Testing of the Profound Matrix™ System (FUFT2002) to evaluate the safety and efficacy of the Profound Matrix System Matrix Pro applicator for the treatment of wrinkles.

Detailed description

This was a retrospective medical record review of subject data from the source study FUFT2002 to evaluate the safety, efficacy, tolerability, and usability of the Profound MatrixTM System with the Matrix Pro Applicator for the treatment of wrinkles.

Interventions

The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks

Sponsors

Candela Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Met eligibility criteria under source study FUFT2002 and enrolled into FUFT2002 study (NCT # pending). 2. Received full face treatment with 27W Matrix Pro applicator only. 3. Have baseline and follow-up assessments obtained. 4. Have photography obtained with the VISIA standardized camera system (Appendix III).

Exclusion criteria

1. Sun exposure during the course of the study. 2. Aesthetic procedures and/or treatments during the course of the study. 3. Any violation of study treatment instructions. 4. Upon inspection, any differences in baseline and follow up photos that would not make evaluation of photos viable (e.g. chin placement, facial expression). 5. Any protocol deviation or change in study visit activities that would jeopardize reliability or validity of the retrospective review

Design outcomes

Primary

MeasureTime frameDescription
Improvement in Facial WrinklesApproximately 6 months following baseline assessmentImprovement in the appearance of wrinkles was assessed by three (3) blinded evaluators comparing photographs taken at Baseline/Pre-treatment and at the 3-month follow-up (post final treatment). Success for an individual subject (an individual responder) was determined if at least two out of three evaluators correctly identified the post-treatment photograph by selecting the correct corresponding photograph side (left or right).

Secondary

MeasureTime frameDescription
Subject Global Aesthetic Improvement Scale (GAIS)Approximately 6 months following baseline assessmentAssessment of Subject Assessment of Improvement via GAIS ratings at the study endpoint (3MFU) using a 5-point scale (-1= worse to 3= very much improved)
Subject Global Aesthetic Improvement Scale (SGAIS)Approximately 4 months following baseline assessmentAssessment of Subject Assessment of Improvement via GAIS ratings at a study timepoint using a 5-point scale (-1= worse to 3= very much improved)

Countries

Israel, United States

Participant flow

Participants by arm

ArmCount
Matrix Pro Applicator
Source study subjects received up to three (3) full-face treatments for wrinkles with Matrix Pro Applicator (27W) Profound Matrix: The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
32
Total32

Baseline characteristics

CharacteristicMatrix Pro Applicator
Age, Continuous50.53 years
STANDARD_DEVIATION 10.99
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
29 Participants
Region of Enrollment
Israel
13 participants
Region of Enrollment
United States
19 participants
Sex: Female, Male
Female
28 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 32
other
Total, other adverse events
5 / 32
serious
Total, serious adverse events
0 / 32

Outcome results

Primary

Improvement in Facial Wrinkles

Improvement in the appearance of wrinkles was assessed by three (3) blinded evaluators comparing photographs taken at Baseline/Pre-treatment and at the 3-month follow-up (post final treatment). Success for an individual subject (an individual responder) was determined if at least two out of three evaluators correctly identified the post-treatment photograph by selecting the correct corresponding photograph side (left or right).

Time frame: Approximately 6 months following baseline assessment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Matrix Pro ApplicatorImprovement in Facial Wrinkles24 Participants
Secondary

Subject Global Aesthetic Improvement Scale (GAIS)

Assessment of Subject Assessment of Improvement via GAIS ratings at the study endpoint (3MFU) using a 5-point scale (-1= worse to 3= very much improved)

Time frame: Approximately 6 months following baseline assessment

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Matrix Pro ApplicatorSubject Global Aesthetic Improvement Scale (GAIS)Very Much Improved4 Participants
Matrix Pro ApplicatorSubject Global Aesthetic Improvement Scale (GAIS)Much Improved13 Participants
Matrix Pro ApplicatorSubject Global Aesthetic Improvement Scale (GAIS)Improved13 Participants
Matrix Pro ApplicatorSubject Global Aesthetic Improvement Scale (GAIS)No Change2 Participants
Matrix Pro ApplicatorSubject Global Aesthetic Improvement Scale (GAIS)Worse0 Participants
Secondary

Subject Global Aesthetic Improvement Scale (SGAIS)

Assessment of Subject Assessment of Improvement via GAIS ratings at a study timepoint using a 5-point scale (-1= worse to 3= very much improved)

Time frame: Approximately 4 months following baseline assessment

Population: data was not collected and analyzed for this outcome

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026